ICD-10 Code D64.1: Secondary sideroblastic anemia due to disease

Key Takeaways

D64.1 is a billable ICD-10-CM code for secondary sideroblastic anemia caused by an underlying disease, not a drug or toxin.

This code describes a manifestation: the underlying disease must be sequenced first using the etiology-manifestation coding convention.

Common coding error: using D64.1 as a primary diagnosis when it must follow the causative condition code.

Pabau’s claims management software helps clinics submit D64.1 with correct sequencing and supporting documentation to reduce denials.

D64.1 is a manifestation code: claims submitted without the underlying disease code in the primary position fail payer edits, generate medical necessity queries, and delay reimbursement.

Reimbursement claims with a date of service on or after October 1, 2015 require ICD-10-CM codes. For practices still using legacy ICD-9-CM code 285.0 in legacy records, the crosswalk to D64.1 is direct. The 2026 ICD-10-CM release confirms D64.1 remains billable and unchanged in its sequencing requirements.

ICD-10 Code D64.1 describes secondary sideroblastic anemia due to disease. Sideroblastic anemia is characterized by erythroblasts containing abnormal iron deposits in the mitochondria, forming the ring sideroblasts visible on bone marrow biopsy. In the secondary form coded by D64.1, this disruption in hemoglobin synthesis results from an underlying systemic condition, not from hereditary causes (D64.0) or drug/toxin exposure (D64.2).

D64.1 is a valid, billable ICD-10-CM diagnosis code for the 2026 fiscal year. It sits within the following code hierarchy:

• Chapter D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
• Block D60-D64: Aplastic and other anemias and other bone marrow failure syndromes
• Category D64: Other anemias
• Code D64.1: Secondary sideroblastic anemia due to disease

The World Health Organization maintains this classification within the WHO ICD-10 browser, where D64.1 appears under the broader aplastic and bone marrow failure syndrome grouping. In US clinical settings, the CDC/NCHS ICD-10-CM web tool confirms the code’s active billable status for 2026. For related blood disorder coding, see the guide on ICD-10 code D75.0: Familial erythrocytosis.

Etiology-manifestation coding convention for D64.1

D64.1 is a manifestation code. The ICD-10-CM Tabular List includes a “code first” instruction that is mandatory, not advisory. This means the code for the underlying causative disease must always be sequenced before D64.1 in the claim’s diagnosis field.

Coders who treat D64.1 like a standalone primary diagnosis generate claim edits that payers catch immediately. Proper sequencing for claims management follows this pattern:

1. First position: The underlying disease code (for example, rheumatoid arthritis or a neoplasm)
2. Second position: D64.1 – Secondary sideroblastic anemia due to disease

Common underlying conditions that drive secondary sideroblastic anemia include rheumatoid arthritis, chronic inflammatory disease, myelodysplastic syndrome (MDS), and neoplasms. Each of these has its own ICD-10-CM code that occupies the principal diagnosis position. D64.1 then captures the manifestation for coding specificity and MS-DRG grouping purposes. For another example of a neoplasm that may underlie hematologic manifestations, see ICD-10 C49.6: Malignant soft tissue neoplasm of the trunk.

Inpatient coders should note that D64.1 is grouped within MS-DRG v43.0 under the appropriate blood disorder DRGs. Sequencing the underlying disease correctly affects which DRG the encounter maps to, which in turn determines the inpatient reimbursement rate. For detailed DRG grouping verification, cross-reference against the CMS ICD-10 codes page.

For additional context on etiology-manifestation conventions applied to other ICD-10-CM conditions, the guidance on ICD-10 codes for hemorrhagic conditions illustrates how sequencing rules apply across different body system manifestations.

D64.1 vs. related sideroblastic anemia codes

The D64 category includes four sideroblastic anemia codes that coders frequently confuse. Selecting the wrong one misrepresents the etiology and may trigger payer audits. The distinction hinges on cause:

The boundary between D64.1 and D64.2 is the most consequential distinction in daily coding. When the patient’s record documents that a medication or toxin caused the iron metabolism disruption, D64.2 applies. When an underlying disease such as rheumatoid arthritis or a neoplasm is the documented cause, D64.1 is correct. Unspecified causation defaults to D64.3 or D64.9, but only after the record is queried and the clinician confirms no more specific etiology can be documented.

For context on how ICD-10-CM handles similar manifestation-etiology pairs in other diagnostic categories, the guide on ICD-10 code D22.4: Melanocytic nevi of scalp and neck illustrates how specificity-driven code selection applies across chapters.

Documentation requirements for D64.1 claims

Accurate ICD-10 Code D64.1 assignment depends on what the treating physician documents, not what the coder infers. These are the minimum documentation elements that support the code and satisfy payer medical necessity review:

• Named underlying disease: The record must explicitly state the causative condition. “Anemia secondary to rheumatoid arthritis” is sufficient. “Anemia, cause unclear” is not.
• Ring sideroblast finding: Bone marrow biopsy or aspiration confirming ring sideroblasts supports the sideroblastic classification. Lab results that only show microcytic anemia without iron studies do not establish the sideroblastic subtype.
• Iron studies: Serum ferritin, serum iron, TIBC, and transferrin saturation help distinguish sideroblastic anemia from iron deficiency anemia. Document these findings in the clinical note.
• Exclusion of drug/toxin cause: If the patient is on medications associated with sideroblastic changes (such as isoniazid or chloramphenicol), the physician should document that these are not the causative agent to support D64.1 over D64.2.

Maintaining structured clinical documentation workflows reduces the chance that a physician’s note lacks the specificity needed to defend D64.1 at audit. Practices using digital intake forms can build condition-specific documentation prompts that surface the required fields at the point of care, before the claim is submitted. An albumin blood test reference is one example of a clinical template that helps clinicians document the laboratory context needed for complex anemia coding.

According to the AAPC Codify ICD-10-CM lookup, D64.1 appears in the Alphabetic Index under “Anemia, sideroblastic, secondary (due to disease).” Coders should verify the entry path in both the Index and the Tabular List before finalizing the code, as required by ICD-10-CM Official Guidelines Section I.A.

For practices managing hematologic documentation across large patient volumes, metabolic health EMR workflows that integrate lab results directly into the clinical record help ensure the specificity needed to support D64.1 at audit. Related device-complication coding is covered in ICD-10 Code T85.72XD: Infected insulin pump, subsequent care, which demonstrates how secondary codes are sequenced after a primary device or disease code.

Cut claim denials on complex anemia codes

Pabau's claims management software helps practices submit D64.1 with correct etiology sequencing, supporting lab documentation attached, and HIPAA-compliant records – so hematology claims pay on the first pass.

Book a demo

Common coding errors and how to avoid them

D64.1 claims fail for predictable reasons. Knowing the error patterns before submission prevents denials that require costly rework.

• Using D64.1 as the principal diagnosis: The most frequent error. Payers running ICD-10-CM edit checks reject claims where D64.1 appears in the primary position without a documented underlying disease code preceding it.
• Assigning D64.9 (anemia, unspecified) instead of D64.1: When the physician’s note clearly documents a secondary sideroblastic etiology, defaulting to D64.9 underspecifies the condition and may not capture the full MS-DRG weight the case warrants.
• Selecting D64.2 when the cause is a disease: Coders sometimes use D64.2 for drug-associated anemia in patients who also have a systemic disease. If the physician attributes the anemia to the disease, D64.1 is the correct code regardless of concurrent medication use.
• Omitting the underlying disease code entirely: Some coding workflows apply D64.1 from problem list triggers without first ensuring the causative disease code is sequenced. The missing first-position code fails claim edits before adjudication.

HIPAA-compliant documentation practices require that code selection reflect the clinical record. Practices with robust HIPAA-compliant documentation practices are better positioned to defend code selection at audit because the evidence trail is clear and complete. Practices looking to grow their patient base while maintaining documentation quality can also benefit from strategies outlined in how to get more patients.

The ICD List diagnostic code reference provides a quick lookup for D64.1 including its DRG groupings, crosswalk data, and inclusion terms, which can help coders verify assignment before the claim goes out. For context on benign hematologic neoplasm coding, see ICD-10 Code D36.0: Benign neoplasm of lymph nodes.

ICD-9-CM crosswalk and 2026 code status for D64.1

ICD-9-CM code 285.0 (Sideroblastic anemia) crosswalks to D64.1 when the documented etiology is an underlying disease. The GEM crosswalk for 285.0 is one-to-many — it can map to D64.0 through D64.9 depending on clinical specificity — so documentation review is required to confirm D64.1 as the correct target. The ICD-10-CM transition effective date was October 1, 2015, when CMS mandated ICD-10-CM for all HIPAA-covered entities.

For the 2026 fiscal year, D64.1 carries no revision flags. Its description, sequencing requirements, and exclude notes are unchanged from the prior year. Coders working with multi-year datasets should verify historical encounters against the applicable year’s tabular list, since code definitions and guidelines can shift annually.

Practices that manage diagnostic coding as part of broader ICD-10-CM documentation programs should keep a structured crosswalk reference on file for codes with active ICD-9 legacy data in their patient population. Related transplant and complication coding is covered in the guides for ICD-10 code T86.31: Heart-lung transplant rejection and ICD-10 Code T86.10: Unspecified issues of kidney transplant.

Conclusion

Secondary sideroblastic anemia is a manifestation, and D64.1 must always follow the underlying disease code. That sequencing rule is the single most consequential coding decision for every D64.1 claim. For practitioners treating related conditions, the ICD-10 code E29.8: Other testicular dysfunction guide demonstrates how systemic disease codes are sequenced in multi-code claims.

Pabau’s claims management software helps hematology and internal medicine practices structure their coding workflows so the etiology always leads, supporting documentation is attached, and D64.1 claims reach the payer correctly the first time. To see how Pabau handles complex diagnostic code sequencing across your patient population, book a demo.

Continue your research

Need a structured framework for clinical documentation accuracy? HIPAA compliance checklist for primary care covers the documentation standards that protect your practice at audit.

Looking for a compliant way to manage hematology patient records? Patient management software for practices explains how integrated record systems support complex diagnosis documentation and accurate code assignment.

Want to streamline your billing workflow across multiple diagnosis codes? Practice management software outlines how a unified system connects clinical documentation to claims submission for faster reimbursement.

Frequently asked questions